Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cytox has developed and commercially launched genetic-based blood tests to assess the risk of developing Alzheimer's disease, enabling early diagnosis and patient stratification. Their platform is used by pharmaceutical and biotechnology companies to support drug development in dementia. The technology is based on leading academic research from the University of Birmingham, University of Oxford, and University College London. The company has validated its test to US CLIA standards and is expanding into differential diagnosis/prognosis services.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Cytox.